Successful management of a lung cancer patient harbouring both EGFR mutation and EML4-ALK fusion gene with disseminated intravascular coagulation

Lung cancer patients harbouring driver oncogene alterations are markedly responsive to molecular target agents, such as epidermal growth factor receptor (EGFR), tyrosine kinase inhibitor (TKI), and echinoderm microtubule-associated protein like 4 – anaplastic lymphoma kinase (EML4-ALK)-TKI. We encou...

Descripció completa

Dades bibliogràfiques

Autors principals:	Kohei Fujita, Megumi Naka, Takanori Ito, Osamu Kanai, Koichi Maekawa, Koichi Nakatani, Tadashi Mio
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2021-01-01
Col·lecció:	Respiratory Medicine Case Reports
Matèries:	Alectinib EGFR mutation EML4-ALK rearrangement Osimertinib Lung adenocarcinoma
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2213007121000551
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!